Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
前收盤價
US$58.84
+US$0.92 · +1.59%
盤中時間採用ET。市場資料可能有所延遲。
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
日內區間
目前US$58.84
52週區間
目前US$58.84
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
18
估值過高
情緒
60
多空交錯
風險
44
風險偏高
動能
61
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
日內區間
目前US$58.84
52週區間
目前US$58.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 34.37億 USD | 33.66億 USD | 29.65億 USD | 25.31億 USD | 24.18億 USD |
| 銷貨成本 | 18.59億 USD | 17.17億 USD | 14.51億 USD | 12.25億 USD | 12.08億 USD |
| 毛利 | 15.78億 USD | 16.5億 USD | 15.13億 USD | 13.06億 USD | 12.1億 USD |
| 研究與開發 | 3.95億 USD | 3.77億 USD | 2.95億 USD | 2.36億 USD | 2.21億 USD |
| 銷售、一般及管理費用 | 9.47億 USD | 8.94億 USD | 7.29億 USD | 6.07億 USD | 5.62億 USD |
| 營業費用 | 13.42億 USD | 13.96億 USD | 10.76億 USD | 8.73億 USD | 7.96億 USD |
| 利息收入 | 1480萬 USD | 930萬 USD | 750萬 USD | 280萬 USD | 90萬 USD |
| 利息支出 | 6030萬 USD | 4790萬 USD | 1640萬 USD | 1610萬 USD | 1430萬 USD |
| 折舊和攤銷 | 2.2億 USD | 1.84億 USD | 1.15億 USD | 8870萬 USD | 8910萬 USD |
| 營業利益 | 2.36億 USD | 2.53億 USD | 4.37億 USD | 4.33億 USD | 4.13億 USD |
| 淨利 | −860萬 USD | 1.13億 USD | 4.27億 USD | 2.97億 USD | 2.77億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$67.00
上漲空間 13.87%年度分割調整後的每股現金分配。
US$0.20
2025年(完整年度)+25.0% 自從 2021
2026年(部分年度):US$0.15
US$0.16
2,021
US$0.20
2,022
US$0.20
2,023
US$0.20
2,024
US$0.20
2,025
US$0.15
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月21日 | US$0.05Quarterly | 2026年9月21日 | 2026年10月7日 |
股息 | 2026年6月22日 | US$0.05Quarterly | 2026年6月22日 | 2026年7月7日 |
股息 | 2026年3月23日 | US$0.05Quarterly | 2026年3月23日 | 2026年4月7日 |
股息 | 2025年12月8日 | US$0.05Quarterly | 2025年12月8日 | 2026年1月2日 |
股息 | 2025年9月23日 | US$0.05Quarterly | 2025年9月23日 | 2025年10月3日 |
股息 | 2025年6月16日 | US$0.05Quarterly | 2025年6月16日 | 2025年6月27日 |
除息 2026年9月21日
US$0.05
Quarterly
2026年9月21日登記 · 支付日 2026年10月7日
除息 2026年6月22日
US$0.05
Quarterly
2026年6月22日登記 · 支付日 2026年7月7日
除息 2026年3月23日
US$0.05
Quarterly
2026年3月23日登記 · 支付日 2026年4月7日
除息 2025年12月8日
US$0.05
Quarterly
2025年12月8日登記 · 支付日 2026年1月2日
除息 2025年9月23日
US$0.05
Quarterly
2025年9月23日登記 · 支付日 2025年10月3日
除息 2025年6月16日
US$0.05
Quarterly
2025年6月16日登記 · 支付日 2025年6月27日
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.97億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1.42億0.08%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR9032.45萬0.13%682億 USD0.05%US$234.43+0.22%
First Trust NYSE Arca Biotechnology Index FundFBT8869.72萬3.07%28.91億 USD0.55%US$265.4+2.00%
Vanguard Extended Market ETFVXF7493.23萬0.08%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS6170.72萬0.18%338.69億 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB4982.65萬0.47%108.2億 USD0.44%US$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY4786.08萬0.19%258.17億 USD0.23%US$669.87+0.54%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
First Trust NYSE Arca Biotechnology Index FundFBT
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
iShares Biotechnology ETFIBB
State Street SPDR S&P MIDCAP 400 ETF TrustMDYAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。